2005). Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol., 23, 17–23., , , et al. (
2004a). Concurrent (CAFT) versus sequential (CAF-T) chemo hormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res. Treat., 88(Suppl. 1), A-37., , , et al. (
2004b). Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc. Am. Soc. Clin. Oncol., 23 (5), Abstr. 510., , , et al. (
1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet, 347, 1713–1727.. (
2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res., 6, R149–R156., , , et al. (
1988). Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother. Oncol., 11, 213–222., , , et al. (
2011. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone, 48, 677–692., and
2014). Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol., 15, 114–122., , , et al. (
2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomised boost versus no boost EORTC 22881-10882 trial. J. Clin. Oncol., 25, 3259–3265., , , et al. (
2014). Breast cancer. In: Recommendations for Cross-Sectional Imaging in Cancer Management, second edition. ed. . London: The Royal College of Radiologists. and , (
2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med., 366, 520–529., , , et al. (
2003). Breast cancer and hormone replacement therapy in the Million Women Study. Lancet, 362, 419–427. and Million Women Study Collaborators. (
2006). Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. Breast, 15 (Suppl. 1), S3–13. (
1996). The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast, 5, 156–157. (
2012). Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J. Clin. Oncol., 30, 709–717., , , et al. (
2002). The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res., 4, 24–29. and (
2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol., 21, 1431–1439., , , et al. (
1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17, 2639–2648., , , et al. (
1999). Sentinel lymph-node mapping in breast cancer. Oncology (Williston Park), 13, 25–34. III. (
2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res., 10, 6622–6628., , , et al. (
2013). Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive risk factors. Br. J. Cancer, 108, 2399–2406., , , et al. (
2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol., 11, 1135–1141., , , et al. (
2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet, 12, 21–29., , , et al. (
2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal (IBIS-II): an international, double-blind, randomized, placebo-controlled trial. Lancet, 383: 1041–1048., , , et al. (
2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet, 381, 805–816., , , et al. (
2014). Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol., 15, 23–34., , , et al. (
2007). Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother. Oncol., 82, 254–264., , , et al. (
2012). Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol., 30, 722–728., , , et al. (
2012). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomized NEAT/BR9601 trials. Br. J. Cancer, 107, 1257–1267., , , et al. (
EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687–1717.
EBCTCG. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet, 378, 1707–1716.
EBCTCG. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet, 379, 432–444.
EBCTCG. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual data for 8135 women in 22 randomised trials. Lancet, 383, 2127–2135.
2006). Breast cancer in pregnancy. J. Obstet. Gynaecol., 26, 1–4. and (
FAST trialists group, 2011). First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother. Oncol., 100, 93–100., , et al. (
1980). Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer, 46, 1–13., , , et al. (
1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353, 1993–2000., , , et al. (
2002). Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med., 347, 1233–1241., , , et al. (
2015). Adjuvant ovarian suppression in premenopausal breast cancer. N. Eng. J. Med., 372, 436–446., , , et al. (
French Adjuvant Study Group. (2001). Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol., 19, 602–611.
2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 355, 2733–2743., , , et al. (
2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol., 12, 236–244., , , et al. (
2004). Is breast cancer survival improving?Cancer, 100, 44–52., , , et al. (
2011). Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis. J. Am. Med. Assoc. 305, 569–575., , , et al. (
2013a). 2 versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomized controlled trial. Lancet. 382, 1021–1028., , , et al. (
2013b). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol., 24, 2206–2223., , , et al. (
2013). Post-operative radiotherapy for ductal carcinoma on situ of the breast. Cochrane Database Syst. Rev., 11. Art. No. CD000563., , , et al. (
2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5-years in 6,953 women with early breast cancer. J. Clin. Oncol., 31(Suppl); abstr. 5., , , et al (
2005). Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Exp. Opin. Pharmacother., 6, 1477–1491., and (
2005). Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J. Clin. Oncol., 23, 11–16., , , et al. (
2013). The UK standardization of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol., 14, 1086–1094., , , et al. (
2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol., 21, 976–983., , , et al. (
2006). Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int. J. Radiat. Oncol. Biol. Phys., 65, 1353–1360., , , et al. (
2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst., 100, 475–482., on behalf of the HABITS Study Group. (
2013). A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pN1mi, ER-positive breast cancer in the UK.Br. J. Cancer, 108, 2250–2258., , , et al. (
2005). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer, 104, 236–239., , , et al. (
2013). Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: long term follow-up of CALGB 9343. J. Clin. Oncol., 31, 2382–2387., , , et al. (
2012). Longer-term outcomes of letrozole versus placebo after 5-years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J. Clin. Oncol., 30, 718–721., , , et al. (
2009). Fluorouracil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without tastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J. Clin. Oncol., 27, 5685–5692., , , et al. (
2009a). Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer, 100, 684–692., and (
2009b). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J. Clin. Oncol., 27, 1177–1183., , , et al. (
2011). Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int. J. Radiat. Oncol. Biol. Phys., 80, 398–402., , , et al. (
2010). Metastatic behavior of breast cancer subtypes. J. Clin. Oncol., 28, 3271–3277., , , et al. (
1986). Risk of lymphoedema following the treatment of breast cancer. Br. J. Surg., 73, 580–584., , , et al. (
2013). The PRIME II trial: wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65-years with early breast cancer managed by breast conservation. San Antonio Breast Cancer Symposium. Abstract S2-01. Presented 11 December 2013., , , et al. (
1990). Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes?Cancer, 66, 2313–2318., , , et al. (
2000). A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer. Adv. Breast Cancer, 2, 1–3. and (
2009). Radiotherapy timing in 4,820 patients with breast cancer: University of Florence experience. Int. J. Radiat. Oncol. Biol. Phys., 73, 365–369., , , et al. (
2006). Randomized multicenter trial of sentinel lymph node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J. Natl Cancer Inst., 98, 599–609., , , et al. (
2005). Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med., 352, 2302–2313., , , et al. (
2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 Study Group. J. Clin. Oncol., 23, 4265–4274., , , et al. (
2013). Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast, 22, 194–196., , , et al. (
2006). Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: a meta-analysis. J. Natl Cancer Inst., 98, 1285–1291., , , et al. (
2011). ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov., 1, 338–351., , , et al. (
1994). ABC of breast diseases. Prognostic factors. Br. Med. J., 309, 1573–1576., , , et al. (
1997). Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J. Sci. Am., 3, 6–12., , , et al. (
2013). Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J. Clin. Oncol., 31, 4488–4495., , , et al. (
NHS Cancer Screening Programmes. (2012). NHS Breast Screening Programme Annual Review.Sheffield: NHS Cancer Screening Programmes.
NICE. (2002). Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. Technology Appraisal Guidance 34. London: NICE.
NICE. (2013a). Familial Breast Cancer. NICE Clinical Guideline. http://guidance.nice.org.uk/CG164/NICEGuidance/pdf/English. London: National Institute for Health and Clinical Excellence.
NICE. (2013b). Gene Expression Profiling and Expanded Immunohistochemistry Tests for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer Management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. NICE Diagnostics Guidance 10. London: National Institute for Health and Clinical Excellence.
NICE. (2013c). Intraoperative Tests (RD-100i OSNA System and Metasin Test) for Detecting Sentinel Lymph Node Metastases in Breast Cancer. NICE Diagnostics Guidance 8. London: National Institute for Health and Clinical Excellence.
NICE. (2014). Early and Locally Advanced Breast Cancer. Diagnosis and Treatment. NICE Clinical Guideline 80.London: National Institute for Health and Care Excellence.
NIH Consensus Conference. (1991). NIH consensus conference. Treatment of early-stage breast cancer. J. Am. Med. Assoc., 265, 391–395.
2013). Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J. Clin. Oncol., 31, 4038–4045., , , et al. (
2002). Superior survival with capecitabine plus docetaxel combination chemotherapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol., 20, 2812–2823., , , et al. (
2004). Is the benefit of post mastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b and c randomized trials.ESTRO 2004, Amsterdam, Abstr. 33., and (
2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Eng. J. Med., 371, 107–118., , , et al. (
2000). Molecular portraits of human breast tumours. Nature, 406, 747–752., , , et al. (
2011a). Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J. Clin. Oncol., 29, 4491–4497., , , et al. (
2011b). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol., 29, 3366–3373., , , et al. (
2008). A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J. Clin. Oncol., 26, 2085–2092., , , et al. (
2013). How long is enough – optimal timing of anti-HER2/neu therapy in the adjuvant setting in early breast cancer. Breast Care, 8, 264–269., and (
2013a). Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-postive early breast cancer (PrefHer): an open-label randomized study. Lancet Oncol., 14, 962–970., , , et al. (
2013b). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. Lancet Oncol., 14, 741–748., , , et al. (
2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trialJ. Natl Cancer Inst., 97, 116–126., , , et al. (
2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol., 12, 1101–1108., , , et al. (
2008). Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev., 34, S1–S18., , , et al. (
2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J. Clin. Oncol., 24, 5664–5671., , , et al. (
2013). Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J. Clin. Oncol., 31(Suppl.); abstr LBA 1001., , , et al. (
2014). Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res., 16, 206–222. and (
SIGN. (2005). Management of Breast Cancer in Women. A National Clinical Guideline. No. 84. Edinburgh: Scottish Intercollegiate Guidelines Network.
SIGN. (2013). SIGN 134. Treatment of Primary Breast Cancer. A National Clinical Guideline.Edinburgh: Scottish Intercollegiate Guidelines Network.
2003). The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am. J. Surg., 186, 337–343. (
2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med., 344, 783–792., , , et al. (
2011). Adjuvant trastuzumab in HER2-postive breast cancer. N. Engl. J. Med., 365, 1273–1283., , , et al. (
2001). Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA, 98, 10869–10874., , , et al. (
2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA, 100, 8418–8423., , , et al. (
2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med., 358, 1663–1671., , , et al. (
2009). Trastuzumab for patients with axillar-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol., 27, 6129–6134., , , et al. (
2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol., 28, 5132–5139., , , et al. (
2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol., 14, 461–471., , , et al. (
2010). Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res., 12(6), R92., , , et al. (
2004). Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur. J. Cancer, 40, 743–753., , , et al. (
UICC. (2009). TNM Classification of Malignant Tumours, 7th edn, ed. , and . New York: Wiley-Liss, pp. 181–193.
2014). Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet, 383, 603–613., , , et al. (
2011). Adjuvant tamoxifen and exemstane in early breast cancer (TEAM): a ransomised phase 3 trial. Lancet, 377, 321–331., , , et al. (
2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med., 347, 1227–1232., , , et al. (
2013). Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial. Lancet Oncol., 14, 1269–1277., , , et al. (
2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med., 349, 546–553., , , et al. (
2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol., 30, 1796–1804., , , et al. (
2006). Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys., 64, 760–764., , , et al. (
2015). Regional nodal irradiation in early-stage breast cancer. N. Eng. J. Med., 373, 307–316., , , et al. (